A Phase I/IIa Open-Label, Dose-Escalation Study to Determine the Safety, Tolerability, and Efficacy of AR100DP1 in Healthy Subjects, and Subjects With Mild to Moderate Atopic Dermatitis

This is a Phase I/IIa Open-Label, Dose-Escalation Study to Determine the Safety, Tolerability, and Efficacy of AR100DP1 in Health Subjects, and Subjects with Mild to Moderate Atopic Dermatitis.

开始日期2020-12-08

申办/合作机构

Arjil Pharmaceuticals LLC

NCT02600611 / Completed临床3期

A Phase 3, Randomized, Double-blind, Multicenter Study to Evaluate the Safety and Efficacy of Intravenous Iclaprim Versus Vancomycin in the Treatment of ABSSSI: REVIVE-1

This is a multicenter, randomized, double-blind study of the efficacy and safety of iclaprim compared to vancomycin for the treatment of skin and skin structure infections.

开始日期2015-11-01

申办/合作机构

Motif Bio Plc

NCT02607618 / Completed临床3期

A Phase 3, Randomized, Double-blind, Multicenter Study to Evaluate the Safety and Efficacy of Intravenous Iclaprim Versus Vancomycin in the Treatment of ABSSSI: REVIVE-2

This is a multicenter, randomized, double-blind study of the efficacy and safety of iclaprim compared to vancomycin for the treatment of skin and skin structure infections.

开始日期2015-11-01

申办/合作机构

Motif Bio Plc

100 项与艾拉普林相关的临床结果

登录后查看更多信息

100 项与艾拉普林相关的转化医学

登录后查看更多信息

100 项与艾拉普林相关的专利（医药）

登录后查看更多信息

项与艾拉普林相关的文献（医药）

2023-03-20·The Journal of antimicrobial chemotherapy

Resistance to antibacterial antifolates in multidrug-resistant Staphylococcus aureus: prevalence estimates and genetic basis.

Article

作者: Louise Kime ; Tina Waring ; Merianne Mohamad ; Benjamin F Mann ; Alex J O'Neill

OBJECTIVES:

Antibacterial antifolate drugs might have a wider role in the management of staphylococcal infection. One factor that could potentially limit their use in this context is pre-existing resistance. Here we explored the prevalence and genetic basis for resistance to these drugs in a large collection (n = 1470) of multidrug-resistant (MDR) Staphylococcus aureus.

METHODS:

Strains were subjected to susceptibility testing to detect resistance to trimethoprim, sulfamethoxazole, co-trimoxazole and the investigational drug, iclaprim. Whole-genome sequences were interrogated to establish the genetic basis for resistance.

RESULTS:

According to CLSI breakpoints, 15.2% of the strains were resistant to trimethoprim, 5.2% to sulfamethoxazole and 4.1% to co-trimoxazole. Using the proposed breakpoint for iclaprim, 89% of the trimethoprim-resistant strains exhibited non-susceptibility to this agent. Sulfamethozaxole resistance was exclusively the result of mutation in the drug target (dihydropteroate synthase). Resistance to trimethoprim and iclaprim also resulted from mutation in the target (dihydrofolate reductase; DHFR) but was more commonly associated with horizontal acquisition of genes encoding drug-insensitive DHFR proteins. Among the latter, we identified a novel gene (dfrL) encoding a DHFR with ∼35% identity to native and known resistant DHFRs, which was confirmed via molecular cloning to mediate high-level resistance.

CONCLUSIONS:

This study provides a detailed picture of the genotypes underlying staphylococcal resistance to antifolate drugs in clinical use and in development. Prevalence estimates suggest that resistance to the diaminopyrimidines (trimethoprim/iclaprim) is not uncommon among MDR S. aureus, and considerably higher than observed for sulfamethoxazole or co-trimoxazole.

2023-01-01·Acta crystallographica. Section E, Crystallographic communications

Iclaprim mesylate displaying a hydrogen-bonded mol-ecular tape.

Article

作者: Sandro Neuner ; Thomas Gelbrich ; Klaus Wurst ; Josef Spreitz ; Sven Nerdinger ; Ulrich J Griesser ; Marijan Stefinovic ; Herwig Schottenberger

The title compound, 2,6-di-amino-5-[(2-cyclo-propyl-7,8-dimeth-oxy-2H-1-benzo-pyran-5-yl)meth-yl]pyrimidin-1-ium methane-sulfonate, C₁₉H₂₃N₄O₃ ⁺·CH₃O₃S^-, is a salt made up from a protonated iclaprim mol-ecule and a mesylate anion. The pyrimidine and chromene units of the iclaprim mol-ecule form an orthogonal arrangement [inter-planar angle of 89.67 (6)°], and the 3-nitro-gen position of the pyrimidine ring is protonated. Four distinct N-H⋯O inter-actions and an additional N-H⋯N hydrogen bond connect iclaprim and mesylate mol-ecules to one another, resulting in an infinite hydrogen-bonded mol-ecular tape structure. The central section of the tape is formed by a sequence of fused hydrogen-bonded rings involving four distinct ring types.

2022-01-01·Frontiers in pharmacology

Efficacy and Safety of Iclaprim for the Treatment of Skin Structures and Soft Tissue Infections: A Methodological Framework.

Article

作者: Lian Wang ; Jin Fan ; Linli Zheng ; Lingmin Chen

Background: Skin and soft tissue infections (SSTIs) are among the most common infections worldwide. They manifest in a variety of forms, such as erysipelas, cellulitis, and necrotizing fasciitis. Antibiotics are the significant method for clinical treatment of SSTIs. This study reported a methodology framework to determine the efficacy and safety of iclaprim in treatment of SSTIs. Methods: We will search the PubMed, EMbase, CNKI, WanFang Data, VIP, and ClinicalTrials.gov from their inception to June 2022 for randomized controlled trials and cohort studies on iclaprim with SSTIs. Two authors will independently screen the eligible studies, assess the quality of the included papers, and extract the required information. Randomized controlled trials will be assessed using the Cochrane risk-of-bias tool. The Newcastle-Ottawa Scale will be used to evaluate observational studies. The quality of the evidence will be evaluated using the Grading of Recommendations Assessment Development and Evaluation system. RevMan 5.3 will be used for the data synthesis and quantitative analysis. Results and Discussions: This study will provide the clinicians with more high-quality evidence to choose iclaprim for patients with SSTIs. Ethics and Dissemination: This systematic review and meta-analysis will be based on published data, so ethical approval is not necessary. The results of this meta-analysis will be published in a peer-reviewed journal.

项与艾拉普林相关的新闻（医药）

2023-01-25

·BioSpace

Methicillin-Resistant Staphylococcus aureus Infection Pipeline Clinical Trials Featuring 25+ companies

New York, USA, Jan. 25, 2023 (GLOBE NEWSWIRE) -- Methicillin-Resistant Staphylococcus aureus Infection Pipeline Clinical Trials Featuring 25+ companies| DelveInsight Methicillin-resistant Staphylococcus aureus (MRSA) is an infection caused by antibiotic-resistant strains of the pathogen Staphylococcus aureus. Rising incidence of Methicillin-resistant Staphylococcus aureus (MRSA) infections is creating health concerns among the population. Manufacturers are focusing on product development and launches for the treatment of Methicillin-resistant Staphylococcus aureus (MRSA). DelveInsight’s 'Methicillin-Resistant Staphylococcus aureus Infection Pipeline Insight 2023' report provides comprehensive global coverage of available, marketed, and pipeline methicillin-resistant Staphylococcusaureus infection therapies in various stages of clinical development. Major pharmaceutical companies are working to advance the pipeline space and future growth potential of the methicillin-resistant Staphylococcusaureus infection pipeline domain. Key Takeaways from the Methicillin-Resistant Staphylococcus aureus Infection Pipeline Report DelveInsight’s methicillin-resistant Staphylococcusaureus infection pipeline report depicts a robust space with 25+ companies and 28+ pipeline drugs for methicillin-resistant Staphylococcusaureus infection treatment. Key methicillin-resistant Staphylococcusaureus infection companies include Trellis Bioscience, LegoChem Biosciences, Aptorum Group, ContraFect, Crystalgenomics, Cellics Therapeutics, MicuRx, Oxford Antibiotic Group, Destiny Pharma, TSRL, Inc., TAXIS Pharmaceuticals, Basilea Pharmaceutica, Helperby Therapeutics, Akagera Medicines, Histogen, Alphamab Co. Ltd, Biocidium Pharmaceuticals, and others are evaluating novel methicillin-resistant Staphylococcusaureus infection drugs candidate to improve the treatment landscape. Promising methicillin-resistant Staphylococcusaureus infection pipeline therapies in various stages of development include TRL1068, Delpazolid, ALS 4, Teicoplanin inhalation, CG 400549, SAAP 148, Exebacase, Marinus, CTI 005, Iclaprim, MRX 4, MRX 7, XF-73, TXA709, ARV-1801, ACX-375C, ABX-605, IBT-V02, BCM-0184, Contezolid, TetramOX, Ceftobiprole, HY-004B8b, HY-005B8a, CG-549, Emricasan, KN043, and several others. Ceftobiprole medocaril, the prodrug of the active moiety ceftobiprole, is a cephalosporin antibiotic for intravenous administration, with rapid bactericidal activity against a wide range of Gram-positive and Gram-negative bacteria. This includes methicillin-susceptible and resistant Staphylococcus aureus (MSSA, MRSA) and susceptible Pseudomonas spp. In October 2022, Basilea Pharmaceutica announced the results from Phase III ERADICATE study, evaluating ceftobiprole in the treatment of adult patients with bacterial bloodstream infections caused by Staphylococcus aureus. Results for the primary efficacy outcomes were consistent in key subgroups including in patients with MSSA or MRSA bloodstream infections at baseline, and in various categories of underlying conditions such as skin and skin structure infections, abdominal abscesses, chronic dialysis, septic arthritis, osteomyelitis, definite right-sided infective endocarditis and in patients with persistent SAB. Basilea also planned to submit a New Drug Application (NDA) for ceftobiprole to the US Food and Drug Administration (FDA) around year-end 2022. Exebacase (CF-301) being developed by ContraFect Corporation is a lysin with potent activity against Staphylococcus aureus ("Staph aureus"). Exebacase has the potential to be the first-in-class of a new treatment for patients with Staph aureus bacteremia. The FDA has granted Breakthrough Therapy designation to exebacase for the treatment of MRSA bloodstream infections (bacteremia), including right-sided endocarditis, when used in addition to SOC antistaphylococcal antibiotics in adult patients, based on the final data from the Phase II superiority trial of exebacase. In July 2022, Destiny Pharma plc announced that it had received an award from the Cystic Fibrosis Foundation. The research project will establish the potential of the Company’s proprietary XF-73 drug as a novel treatment for cystic fibrosis patients infected with methicillin-resistant Staphylococcus aureus (MRSA). CTI-005 is for the treatment of Methicillin Resistance Staphylococcus Aureus (MRSA) Pneumonia and has been granted IND allowance from the US FDA. The potent RBC-NS has the membrane lipids and receptors that a normal red blood cell has, however, the high surface-volume ratio of the RBC-NS allows it to act as a decoy. This characteristic allows the RBC-NS to bind and neutralize toxins, auto-antibodies, and bacterial infections. The pore-forming toxins emitted by MRSA can be effectively absorbed and neutralized by RBC-NS. Request a sample and discover the recent advances in methicillin-resistant Staphylococcusaureus infection treatment drugs @ Methicillin-Resistant Staphylococcus aureus Infection Pipeline Report The methicillin-resistant Staphylococcusaureus infection pipeline report provides detailed profiles of pipeline assets, a comparative analysis of clinical and non-clinical stage methicillin-resistant Staphylococcusaureus infection products, inactive and dormant assets, a comprehensive assessment of driving and restraining factors, and an assessment of opportunities and risks in the methicillin-resistant Staphylococcusaureus infection pipeline landscape. Methicillin-Resistant Staphylococcus aureus Infection Overview Methicillin-resistant Staphylococcus aureus (MRSA) infections are caused by bacteria that have attained resistance from several antibiotics that treat diseases caused by Staphylococcus bacteria. The common patients of Methicillin-resistant Staphylococcus aureus (MRSA) infections are patients that have been in hospitals or healthcare settings for a long duration where the bacteria is found commonly. MRSA infections are known as healthcare-associated MRSA (HA-MRSA) if infected in hospitals. Such infections can spread to healthcare workers through invasive procedures, which are further transmitted to several patients by touching and operating with bare hands. Other MRSA infections occur in a considerable population of healthy people. People associated with community-associated MRSA (CA-MRSA) show symptoms appearing as painful skin boils. It further spreads through physical contact between individuals. The population at higher risk includes people surrounded by a significant number of people and childcare workers. MRSA infections might look like red bumps, pimples, or spider bites, accompanied by pus and fever. Find out more about methicillin-resistant Staphylococcusaureus infection treatment drugs @ Drugs for Methicillin-Resistant Staphylococcus aureus Infection Treatment A snapshot of the Methicillin-Resistant Staphylococcus aureus Infection pipeline drugs mentioned in the report: Drug Company Phase MoA RoA Ceftobiprole Basilea Pharmaceutica Phase III Cell wall inhibitors; Peptidyltransferase inhibitors Intravenous CG 549 CrystalGenomics Phase II Enoyl-ACP reductase inhibitors; Fatty acid synthase expression inhibitors; Fatty acid synthetase complex inhibitors Oral BCM-0184 Biocidium Pharmaceuticals Phase I NA Oral/Topical TRL1068 Trellis Bioscience Phase I Bacterial biofilm inhibitors Intravenous ALS 4 Aptorum Group Phase I Bacterial virulence inhibitors Oral EVX-B1 Evaxion Biotech Preclinical Immunostimulants NA Emricasan Histogen Preclinical Apoptosis inhibitors; Caspase inhibitors NA TarO inhibitor Prokaryotics Discovery Cell membrane inhibitors; Cell wall inhibitors NA Learn more about the emerging methicillin-resistant Staphylococcusaureus infection pipeline therapies @ Methicillin-Resistant Staphylococcus aureus Infection Clinical Trials Methicillin-Resistant Staphylococcus aureus Infection Therapeutics Assessment The methicillin-resistant Staphylococcus aureus infection pipeline report proffers an integral view of methicillin-resistant Staphylococcusaureus infection emerging novel therapies segmented by stage, product type, molecule type, mechanism of action, and route of administration. Scope of the Methicillin-Resistant Staphylococcus aureus Infection Pipeline Report Coverage: Global Therapeutic Assessment By Product Type: Mono, Combination, Mono/Combination Therapeutic Assessment By Clinical Stages: Pre-clinical, Discovery, Discontinued, Inactive, Phase I, Phase II, Phase III Therapeutics AssessmentBy Route of Administration: Oral, Parenteral, Intravenous, Subcutaneous, Topical. Therapeutics AssessmentBy Molecule Type: Monoclonal Antibody, Peptides, Polymer, Small molecule, Gene therapy Therapeutics AssessmentBy Mechanism of Action: Cell wall inhibitors; Peptidyltransferase inhibitors, Enoyl-ACP reductase inhibitors; Fatty acid synthase expression inhibitors; Fatty acid synthetase complex inhibitors, Bacterial biofilm inhibitors, Bacterial virulence inhibitors, Immunostimulants, Apoptosis inhibitors; Caspase inhibitors, Cell membrane inhibitors; Cell wall inhibitors Key Methicillin-Resistant Staphylococcus aureus Infection Companies: Trellis Bioscience, LegoChem Biosciences, Aptorum Group, ContraFect, Crystalgenomics, Cellics Therapeutics, MicuRx, Oxford Antibiotic Group, Destiny Pharma, TSRL, Inc., TAXIS Pharmaceuticals, Basilea Pharmaceutica, Helperby Therapeutics, Akagera Medicines, Histogen, Alphamab Co. Ltd, Biocidium Pharmaceuticals, and others. Key Methicillin-Resistant Staphylococcus aureus Infection Pipeline Therapies: TRL1068, Delpazolid, ALS 4, Teicoplanin inhalation, CG 400549, SAAP 148, Exebacase, Marinus, CTI 005, Iclaprim, MRX 4, MRX 7, XF-73, TXA709, ARV-1801, ACX-375C, ABX-605, IBT-V02, BCM-0184, Contezolid, TetramOX, Ceftobiprole, HY-004B8b, HY-005B8a, CG-549, Emricasan, KN043, and others. Dive deep into rich insights for new drugs for methicillin-resistant Staphylococcusaureus infection treatment; visit @ Methicillin-Resistant Staphylococcus aureus Infection Drugs Table of Contents 1. Methicillin-Resistant Staphylococcus aureus Infection Pipeline Report Introduction 2. Methicillin-Resistant Staphylococcus aureus Infection Pipeline Report Executive Summary 3. Methicillin-Resistant Staphylococcus aureus Infection Pipeline: Overview 4. Analytical Perspective In-depth Commercial Assessment 5. Methicillin-Resistant Staphylococcus aureus Infection Pipeline Therapeutics 6. Methicillin-Resistant Staphylococcus aureus Infection Pipeline: Late Stage Products (Pre-registration) 7. Methicillin-Resistant Staphylococcus aureus Infection Pipeline: Late Stage Products (Phase III) 7.1 Ceftobiprole: Basilea Pharmaceutica 8. Methicillin-Resistant Staphylococcus aureus Infection Pipeline: Mid Stage Products (Phase II) 8.1 CG549: CrystalGenomics 9. Methicillin-Resistant Staphylococcus aureus Infection Pipeline: Early Stage Products (Phase I) 9.1 TRL1068: Trellis Bioscience 10. Methicillin-Resistant Staphylococcus aureus Infection Pipeline Therapeutics Assessment 11. Inactive Products in the Methicillin-Resistant Staphylococcus aureus Infection Pipeline 12. Company-University Collaborations (Licensing/Partnering) Analysis 13. Key Companies 14. Key Products in the Methicillin-Resistant Staphylococcus aureus Infection Pipeline 15. Unmet Needs 16. Market Drivers and Barriers 17. Future Perspectives and Conclusion 18. Analyst Views 19. Appendix For further information on the methicillin-resistant Staphylococcusaureus infection pipeline therapeutics, reach out @ Methicillin-Resistant Staphylococcus aureus Infection Treatment Drugs Related Reports Methicillin-Resistant Staphylococcus aureus Epidemiology Forecast Methicillin-Resistant Staphylococcus aureus Epidemiology Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, and the methicillin-resistant Staphylococcusaureus epidemiology trends. Methicillin-Resistant Staphylococcus aureus Infection Market Methicillin-Resistant Staphylococcus aureus Market Insights, Epidemiology, and Market Forecast – 2032 report delivers an in-depth understanding of the market trends, market drivers, market barriers, and key methicillin-resistant Staphylococcusaureus infection companies, including Trellis Bioscience, LegoChem Biosciences, Aptorum Group, Allergan, iNtRON Biotechnology, Neupharma, ImmuPharma, Lytix Biopharma, CrystalGenomics, AIMM Therapeutics, among others. Staphylococcus aureus Bacteremia Pipeline Staphylococcus aureus Bacteremia Pipeline Insight – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug pro including clinical and non-clinical stage products, and the key Staphylococcus aureus Bacteremia companies, including ContraFect, Armata Pharmaceuticals, iNtRON Biotechnology, Durata Therapeutics, Cipher Pharmaceuticals, XBiotech, Basilea Pharmaceutica, Genentech, among others. Hospital Acquired Methicillin-Resistant Staphylococcus aureus Infections Pipeline Hospital Acquired Methicillin-Resistant Staphylococcus aureus Infections Pipeline Insight – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug pro including clinical and non-clinical stage products, and the key Hospital Acquired Methicillin-Resistant Staphylococcus aureus Infections companies, including Trellis Bioscience, LegoChem Biosciences, Aptorum Group, Allergan, iNtRON Biotechnology, Neupharma, ImmuPharma, Lytix Biopharma, CrystalGenomics, AIMM Therapeutics, among others. Other Trending Reports Treatment Resistant Depression Market | Advanced Renal Cell Carcinoma Market | Brain Cancer Market | Centronuclear Myopathy Market | Head And Neck Squamous Cell Carcinoma Market | Acquired Immunodeficiency Syndrome Market | Acute Intermittent Porphyria Market | Neurovascular Devices Market | Defibrillators Market | Ventricular Hypertrophy Market | Urolithiasis Market | Alopecia Areata Market | Autonomic Dysfunction Market | Acute Ischemic Stroke Ais Market | Adenoid Cystic Carcinoma Market | Aspergillosis Market | Biliary Atresia Market | Biliary Tumor Market | Chronic Inducible Urticaria Market | Chronic Insomnia Market | Critical Limb Ischemia Market | Endometriosis Pain Market | Generalized Anxiety Disorder Gad Market | Hallux Valgus Market | Hemophilia B Market | Immunologic Deficiency Syndrome Market | Neuroblastoma Market | Neuromodulation Devices Market | Neurovascular Thrombectomy Devices Market | Osteosarcoma Market | Pemphigus Vulgaris Market | Progressive Familial Intrahepatic Cholestasis Market | Pruritus Market | Radiation Toxicity Market | Pulmonary Hypertension Associated With Interstitial Lung Disease Market | Cluster Headaches Market | Foot And Ankle Devices Market | Intravenous Immunoglobulin Market | Bile Duct Neoplasm Market | Blood Glucose Monitoring Systems Market | Rett Syndrome Market | Tissue Heart Valves Market | Cardiac Biomarkers Testing Devices Market | Subscription Healthcare | Hepatorenal Syndrome Market | Central Venous Catheters Market | Continuous Renal Replacement Therapy Machines Market | Nonalcoholic Steatohepatitis Market | Necrotizing Enterocolitis Market | Cardiac Amyloidosis Market | Artificial Iris Market | Aortic Aneurysm Stent Grafts Market | Polypoidal Choroidal Vasculopathy Market | Adrenal Crisis Market | Hearing Implants Market | Image Guided Surgery Devices Market | Angioedema Market | Bladder Cancer Market Related Healthcare Services Healthcare Consulting Healthcare Competitive Intelligence Services Healthcare Asset Prioritization Services About DelveInsight DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. Connect with us atLinkedIn Contact Us Shruti Thakur info@delveinsight.com +1(919)321-6187

临床3期临床2期临床结果

2022-06-16

·PRNewswire

Worldwide Anti-aging Therapeutics Industry to 2040 - Rising Aging Population is Driving Growth

DUBLIN, June 16, 2022 /PRNewswire/ -- The "Anti-aging Therapeutics Market - Distribution by Type of Molecule, Type of Aging and Key Geographies - Industry Trends and Global Forecasts, 2022-2040" report has been added to ResearchAndMarkets.com's offering. This report features an extensive study of the current market landscape and future potential of anti-aging therapeutics over the next decade. The study features an in-depth analysis of the key drivers and trends related to this domain. The advancements in health care and available technologies have inadvertently led to an increase in the life expectancy of individuals. However, this has also led to a rise in the aging population worldwide. According to the United Nations, the aforementioned trend is one of the key transformations observed in the 21st century; it is expected to have an impact on all sections of the society. Aging is linked to a variety of diseases, including cardiovascular disorders, neurodegenerative disorders, oncological disorders and musculoskeletal disorders, which further puts heavy economic and psychological burden on the patients, their families and the society. As per the World Health Organization, in 2020, close to 1 billion people were estimated to be aged 65 or above, globally. In addition, the share of elderly population is expected to increase from 9.3% in 2020 to 16% in 2050. Aging biology is still a largely unexplored field, in terms of the development of safe and effective novel pharmacotherapies. Anti-aging therapeutics, therefore, is an emerging field of medical science focused on reducing or reversing the underlying causes of aging through different mechanisms, in order to extend healthy lifespan of humans. Given the rapidly growing aging population, the ongoing efforts to discover drugs that enhance the lifespan of an individual by targeting the pathogenesis of aging have become a popular topic for research. At present, various anti-aging products and devices, including direct-to-consumer nutraceuticals, plastic surgeries, cosmetics, skincare products and devices, are available in the market to slow the process of aging. Further, several start-ups and academic / research institutes across the world are evaluating various types of anti-aging therapeutics, including stem cell therapies, metformin, rapamycin, resveratrol and senolytics (drugs that selectively clear senescent cells), in multiple preclinical / clinical studies. Owing to the encouraging results demonstrating the ability of novel drugs in delaying the aging process, capital investments worth USD 4 billion have been made by various private and public sector investors in the last five years to fund product development initiatives. Moreover, over 660 patents related to anti-aging therapeutics have been recently filed / granted, demonstrating the continued innovation in this domain. Driven by the growing aging population, ongoing pace of innovation in this field and financial support from investors, the anti-aging therapeutics market is anticipated to witness substantial growth in the mid to long-term. Amongst other elements, the report includes: A detailed assessment of the current market landscape of anti-aging therapeutics, featuring information on phase of development (commercial, phase II, phase I / II, phase I, clinical (phase unknown), discovery / preclinical and undisclosed), type of aging (cellular aging, metabolic aging, immune aging, others and undisclosed), type of molecule (biologics and small molecules), mechanism of action (senolytic, cell regeneration, mammalian target of rapamycin (mTOR) inhibitor / modulator, adenosine monophosphate (AMP)-kinase / AMP activator, mitochondria inhibitor / modulator and others) and type of developer (industry and non-industry). In addition, the chapter features analyses of anti-aging therapeutic developers based on parameters, such as year of establishment, company size, location of headquarters and leading developers (in terms of number of pipeline candidates). A competitiveness analysis of anti-aging therapeutic developers, based on various relevant parameters, namely supplier power (based on the experience of the developer) and company competitiveness (based on highest phase of development, type of aging and type of molecule). An analysis of partnerships that have been inked by stakeholders engaged in this domain, during the period 2018-2022. Further, the partnership activity in this domain has been analyzed based on various parameters, such as year of partnership, type of partnership, most active players (in terms of number of partnerships), type of partner and regional distribution of collaborations. A detailed analysis of investments that have been made into companies which are developing proprietary anti-aging therapeutics, during period 2018-2022. The various types of funding instances reported in this domain include pre-seed financing, seed financing, venture capital financing, capital raised from IPOs and subsequent public offerings, grants, crowdfunding, and donations. An in-depth analysis of the various patents that have been filed / granted related to anti-aging therapeutics, during 2018-2022, taking into consideration parameters, such as publication year, type of patent, geographical region, CPC symbols, key focus areas, type of applicant, patent age and leading players (in terms of size of intellectual property portfolio). It also features a patent benchmarking analysis and a detailed valuation analysis. A detailed review of more than 220 peer-reviewed, scientific articles related to research on anti-aging therapeutics, during the period 2018-2022, based on several relevant parameters, such as year of publication, type of publication, popular keywords and geography of affiliations. The chapter also provides information on the most popular publisher, most popular journal, most popular affiliations and most popular funding institutes (in terms of number of articles published). A qualitative analysis, highlighting the five competitive forces prevalent in this domain, including threats for new entrants, bargaining power of suppliers, bargaining power of buyers, threats of substitute products and rivalry among existing competitors. Elaborate profiles of prominent players engaged in the development of anti-aging therapeutics, featuring a brief overview of the company, details related to its product portfolio, recent developments and an informed future outlook. Key Questions Answered Who are the leading players engaged in the development of anti-aging therapeutics? What types of partnership models are commonly adopted by industry stakeholders engaged in this industry? Who are the key investors in the anti-aging therapeutics domain? How is the intellectual property landscape in this field likely to evolve in the foreseen future? What is the evolving trend of publications focused on anti-aging therapeutics? What are the key value drivers that are likely to influence the evolution of this upcoming market? How is the current and future market opportunity likely to be distributed across key market segments? Key Topics Covered: 1. PREFACE 2. EXECUTIVE SUMMARY 3. INTRODUCTION 4. MARKET LANDSCAPE 5. COMPANY COMPETITIVENESS ANALYSIS 5.1. Chapter Overview 5.2. Assumptions and Key Parameters 5.3. Methodology 5.4. Anti-aging Therapeutics: Company Competitiveness Analysis 5.4.1. Small Companies 5.4.2. Mid-sized and Large Companies 6. PARTNERSHIPS AND COLLABORATIONS 6.1. Chapter Overview 6.2. Anti-aging Therapeutics: Partnerships and Collaborations 6.2.1 Analysis by Year of Partnership 6.2.2. Analysis by Type of Partnership 6.2.3. Analysis by Year and Type of Partnership 6.2.4. Leading Players: Analysis by Number of Partnerships 6.2.5. Analysis by Type of Partner 6.2.6. Analysis by Type of Agreement 6.2.7. Analysis by Region 6.2.7.1. Intercontinental and Intracontinental Deals 6.2.7.2. International and Local Deals 7. FUNDING AND INVESTMENTS 7.1. Chapter Overview 7.2. Anti-aging Therapeutics: Funding and Investments 7.2.1. Analysis of Instances by Year 7.2.2. Analysis of Amount Invested by Year 7.2.3 Analysis of Instances by Type of Funding 7.2.4. Analysis of Amount Invested by Type of Funding 7.2.5. Analysis by Type of Investor 7.2.6. Analysis by Focus Area 7.2.7. Analysis of Amount Invested by Region 7.2.8. Analysis of Amount Invested by Country 7.2.9. Most Active Investors: Analysis by Number of Instances 7.2.10. Most Active Players: Analysis by Number of Instances 7.2.11. Most Active Players: Analysis by Amount Invested 8. PATENT ANALYSIS 8.1. Chapter Overview 8.2. Scope and Methodology 8.3. Anti-aging Therapeutics: Patent Analysis 8.3.1. Analysis by Type of Patent 8.3.2. Analysis by Patent Publication Year 8.3.3. Analysis of Granted Patents by Year 8.3.4. Analysis by Geography 8.3.5. Analysis by CPC Symbols 8.3.6. Analysis by Type of Applicant 8.3.7. Analysis by Emerging Focus Areas 8.3.8. Analysis by Patent Age 8.3.9. Leading Industry Players: Analysis by Number of Patents 8.3.10. Leading Non-Industry Players: Analysis by Number of Patents 8.3.11. Leading Individual Assignees: Analysis by Number of Patents 8.4. Anti-aging Therapeutics: Patent Benchmarking 8.4.1. Analysis by Patent Characteristics 8.5. Anti-aging Therapeutics: Patent Valuation 9. PUBLICATION ANALYSIS 9.1. Chapter Overview 9.2. Scope and Methodology 9.3. Anti-aging Therapeutics: Publication Analysis 10. PORTER'S FIVE FORCES ANALYSIS 11. COMPANY PROFILES 11.1. AgelessRx 11.1.1. Company Overview 11.1.2. Product Portfolio 11.1.3. Recent Developments and Future Outlook 11.2. ANOVA Institute for Regenerative Medicine 11.2.1. Company Overview 11.2.2. Product Portfolio 11.2.3. Recent Developments and Future Outlook 11.3. Betterhumans 11.3.1. Company Overview 11.3.2. Product Portfolio 11.3.3. Recent Developments and Future Outlook 11.4. BioAge Labs 11.4.1. Company Overview 11.4.2. Product Portfolio 11.4.3. Recent Developments and Future Outlook 11.5. bioXcellerator 11.5.1. Company Overview 11.5.2. Product Portfolio 11.5.3. Recent Developments and Future Outlook 11.6. Cambrian Biopharma 11.6.1. Company Overview 11.6.2. Product Portfolio 11.6.3. Recent Developments and Future Outlook 11.7. Gero.ai 11.7.1. Company Overview 11.7.2. Product Portfolio 11.7.3. Recent Developments and Future Outlook 11.8. Mayo Clinic 11.8.1. Company Overview 11.8.2. Product Portfolio 11.8.3. Recent Developments and Future Outlook 11.9. Rejuvenate Bio 11.9.1. Company Overview 11.9.2. Product Portfolio 11.9.3. Recent Developments and Future Outlook 11.10. UT Health San Antonio 11.10.1. Company Overview 11.10.2. Product Portfolio 11.10.3. Recent Developments and Future Outlook 12. MARKET FORECAST AND OPPORTUNITY ANALYSIS 12.1. Forecast Methodology and Key Assumptions 12.2. Global Anti-aging Therapeutics Market, 2022-2040 12.2.1. Anti-aging Therapeutics Market: Analysis by Type of Molecule 12.2.2. Anti-aging Therapeutics Market: Analysis by Type of Aging 12.2.3. Anti-aging Therapeutics Market: Analysis by Geography 12.2.3.1. Anti-aging Therapeutics Market in North America, 2022-2040 12.2.3.2. Anti-aging Therapeutics Market in Europe, 2022-2040 12.2.3.3. Anti-aging Therapeutics Market in Asia Pacific, 2022-2040 12.2.3.4. Anti-aging Therapeutics Market in Rest of the World, 2022-2040 12.2.4. Anti-aging Therapeutics: Forecast of Individual Product Sales 12.2.4.1. bioXgel (PRP) (bioXcellerator): Estimated Sales Revenues 12.2.4.2. AR-100 (Rejenevie Therapeutics): Estimated Sales Revenues 12.2.4.3. BGE-117 (BioAge Labs): Estimated Sales Revenues 12.2.4.4. Dasatinib and Quercetin (TruDiagnostic): Estimated Sales Revenues 12.2.4.5. MYMD-1 (MyMD Pharmaceuticals): Estimated Sales Revenues 12.2.4.6. TRIIM Treatment (Intervene Immune): Estimated Sales Revenues 12.2.4.7. Rapamycin (AgelessRx): Estimated Sales Revenues 12.2.4.8. Sarconeos (BIO101) (Biophytis): Estimated Sales Revenues 13. EXECUTIVE INSIGHTS 13.1. Chapter Overview 13.2. Gero.ai 13.2.1 Company Snapshot 13.2.2. Interview Transcript: Peter Fedichev (Co-founder and Chief Executive Officer) 13.3. Betterhumans 13.3.1. Company Snapshot 13.3.2. Interview Transcript: James Clement (President) 13.4. CytoMed Therapeutics 13.4.1. Company Snapshot 13.4.2. Interview Transcript: Wee Kiat Tan (Chief Operating Officer) 13.5. Cambrian Biopharma 13.5.1 Company Snapshot 13.5.2. Interview Transcript: Rosa Argyropoulos (Senior Director of Global Corporate Communications) 13.6. Landmark Medical Centre 13.6.1 Company Snapshot 13.6.2. Interview Transcript: Lucas Luk Tien Wee (Director and Consultant Obstetrician and Gynaecologist) 14. APPENDIX I: TABULATED DATA 15. APPENDIX I1: LIST OF COMAPANIES AND ORGANIZATIONS For more information about this report visit Media Contact: Research and Markets Laura Wood, Senior Manager [email protected] For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 U.S. Fax: 646-607-1904 Fax (outside U.S.): +353-1-481-1716 SOURCE Research and Markets

细胞疗法小分子药物合作

2022-06-08

·PRNewswire

Anti-aging Therapeutics Market worth $ 2013.5 Million by 2030 - Exclusive Report by InsightAce Analytic

JERSEY CITY, N.J., June 8, 2022 /PRNewswire/ -- InsightAce Analytic Pvt. Ltd. announces the release of market assessment report on "Global Anti-aging Therapeutics Market (Type of Molecule (Biologics and Small Molecules), Type of Aging (Cellular Aging, Immune Aging, Metabolic Aging and Others), Mechanism of Action (Senolytic, Cell Regeneration, mTOR inhibitor/Modulator, AMP-kinase/AMP Activator, Mitochondria Inhibitor/Modulator and Others))– Industry Analysis, Competitive Landscape, Revenue Forecast 2020-2030" According to the latest research by InsightAce Analytic, the global Anti-aging Therapeutics market size valued at US$ 518.86 million in 2021, and it is expected to reach US$ 2013.51 million in 2030, recording a promising CAGR of 16.53% during the period of 2022-2030. Request for Sample Pages: Aging populations are increasing the prevalence of age-related illnesses, causing individual and social concerns. The demand for effective regenerative medicine solutions for the elderly is higher than ever. Anti-Aging Therapeutics has emerged as a new medical science field. Anti-aging diagnosis and medicine, which is a subset of medical and healthcare, uses modern science and medical technology to identify, prevent, cure, and reverse age-related dysfunctions, illnesses, and diseases. Several cell, insect, and animal models may be useful beginning areas in the development of anti-aging medicines prior to human trials. Interest and expenditure in anti-aging medicines are rising exponentially as living conditions improve. Several companies have also focused their efforts on stem cells and regenerative medicine. Given the numerous applications of stem cells, applications in regenerative medicine are far beyond ageing disorders and illnesses. Nonetheless, a few organizations have concentrated specifically on age-related problems. For instance, In Feb 2021, Cambrian Biopharma received $60 million in private funding for the development of anti-aging medications. The "Nine Hallmarks of Aging," which include cellular senescence, persistent tissue inflammation, and mitochondrial malfunction, are the focus of research of Cambrian scientists. Researchers are utilizing advancements in immunology, genomics, and epigenetics, as well as technologies ranging from gene editing to novel stem cell treatments. There is substantial potential for anti-aging therapeutics companies that effectively launch longevity treatments. Despite these encouraging breakthroughs in the field of ageing, a number of barriers will become obvious once an anti-aging medicine undergoes the demanding clinical trial procedure. Market growth is primarily related to a rise in demand for individualized, precise, preventative, and participative ageing therapies, as well as an increase in the Geriatric Population. As a result, as the number of the elderly rises, so does the need for anti-aging treatments. Increased technological advancements and R&D spending on anti-ageing products are propelling the market forward. To meet the growing demand for technologically advanced solutions among customers, companies in the field have mainly developed revolutionary anti-ageing therapeutics products. With a rising healthcare industry, North America is expected to have the largest revenue shares in 2022. Research and development into pharmaceuticals are rising in major economies such as the United States and Canada, and this is due to the increased investment in pharmaceutical design, production as well as research into senescent cells. Moreover, Asia Pacific is the world's most populous region, and it has a sizable market for anti-aging therapeutics. The ever-increasing proportion of elderly people in the population is a potential customer base for anti-aging treatments, driving regional growth. Enquiry Before Buy: Major key Players in the Anti-aging Therapeutics market are AgelessRx, ANOVA Institute for Regenerative Medicine, Betterhumans, BioAge Labs, BIOPHYTIS BSA, bioXcellerator, Cambrian Biopharma, CytoMed Therapeutics, Gero.ai, Rejuvenate Bio, Rejenevie Therapeutics, UT Health San Antonio, MyMD Pharmaceuticals, Intervene Immune, Inc. , CohBar, Inc., Alkahest, Athersys Inc, BHB Therapeutics, Biosplice, Cyclo Therapeutics, Denali Therapeutics, Elysium Health, Genome Protection, GenSight Biologics, Intervene Immune, Khondrian, Longeveron, LyGenesis, Mesoblast, Minovia Therapeutics, Mitobridge, Navitor Pharmaceuticals, NeuroTrack, Nuchido, NuSirt, OneSkin Technologies, PharmatrophiX, Proteostasis Therapeutics, Retrotope, Stealth Biotherapeutics, TA Sciences, Unity Biotechnology Younger Phenotype, and Other Prominent Players Recent Key Developments: In Feb 2022, Cambrian Biopharma announced that it had entered into a licence arrangement with Novartis to promote innovative, selective drugs that target the mechanistic target of rapamycin (mTOR) pathway. These compounds were conceived and characterized by Novartis. Cambrian Biopharma informed via a statement that the licensed assets are structural analogues of the FDA-approved drug rapamycin. This drug has been shown to prevent or reverse multiple age-related health deficits in mice and to extend their average lifespan by up to 31 %, according to the information provided by Cambrian Biopharma. In May 2019, Rejenevie™ Therapeutics announced the initiation of the Company's Phase II clinical trial to explore the safety and effectiveness of its unique AR-100 immune restoration treatment to increase the function of the ageing immune system. The clinical-stage biotechnology company develops first-in-world stem cell restoration medicines targeting age-related disorders. In April 2022, MyMD Pharmaceuticals Inc. accelerated the dosing of additional patients in the Company's fully funded Phase 2 clinical study of lead drug candidate MYMD-1 as a treatment for delaying ageing and extending a healthy lifespan. The double-blind, placebo-controlled, randomized Phase 2 research (NCT05283486) explores the effectiveness, safety, and pharmacokinetics of MYMD-1® in the treatment of people aged 65 years or older with chronic inflammation associated with sarcopenia/frailty. Market Segments Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2020 to 2030 based on Type of Molecule Biologics Small Molecules Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2020 to 2030 based on Type of Aging Cellular Aging Immune Aging Metabolic Aging Others Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2020 to 2030 based on Mechanism of Action Senolytic Cell Regeneration mTOR inhibitor/Modulator AMP-kinase/AMP Activator Mitochondria Inhibitor/Modulator Others Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2020 to 2030 based on Region North America Europe Asia Pacific Latin America Middle East & Africa North America Anti-aging Therapeutics market revenue (US$ Million) by Country, 2020 to 2030 U.S. Canada Europe Anti-aging Therapeutics market revenue (US$ Million) by Country, 2020 to 2030 Germany France Italy Spain Russia Rest of Europe Asia Pacific Anti-aging Therapeutics market revenue (US$ Million) by Country, 2020 to 2030 India China Japan South Korea Australia & New Zealand Latin America Anti-aging Therapeutics market revenue (US$ Million) by Country, 2020 to 2030 Brazil Mexico Rest of Latin America Middle East & Africa Anti-aging Therapeutics market revenue (US$ Million) by Country, 2020 to 2030 GCC Countries South Africa Rest of Middle East & Africa Why should buy this report: To receive a comprehensive analysis of the prospects for global Anti-aging Therapeutics market To receive industry overview and future trends of global Anti-aging Therapeutics market To analyse the Anti-aging Therapeutics market drivers and challenges To get information on Anti-aging Therapeutics market size value (US$ Mn) forecast till 2030 Major Investments, Mergers & Acquisition in global Anti-aging Therapeutics market industry For Customization @ Other Related Reports Published by InsightAce Analytic: Global Longevity and Anti-Senescence Therapy Market Global Antisense Oligonucleotide Therapeutics Market Global Anti-Ageing Products Services and Devices Market About Us: InsightAce Analytic is a market research and consulting firm that enables clients to make strategic decisions. Our qualitative and quantitative market intelligence solutions inform the need for market and competitive intelligence to expand businesses. We help clients gain competitive advantage by identifying untapped markets, exploring new and competing technologies, segmenting potential markets and repositioning products. Our expertise is in providing syndicated and custom market intelligence reports with an in-depth analysis with key market insights in a timely and cost-effective manner. Contact Us: InsightAce Analytic Pvt. Ltd. Tel.: +1 718 593 4405 Email: [email protected] Site Visit: Follow Us on LinkedIn @ bit.ly/2tBXsgS Follow Us On Facebook @ bit.ly/2H9jnDZ SOURCE InsightAce Analytic Pvt. Ltd.

寡核苷酸小分子药物并购

100 项与艾拉普林相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D08337	艾拉普林	-	DB06358

研发状态

适应症	最高研发状态	国家/地区	公司
呼吸机相关性肺炎	终止	-	Arpida AG 更多
细菌性皮肤疾病	无进展	美国更多	Arpida AG 更多
皮肤和皮肤结构感染	无进展	罗马尼亚更多	Motif Bio Plc 更多

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT04220411 (CTgov)	临床1/2期	特应性皮炎	17	AR100DP1 (AR100DP1 (1.25%)_Phase I)	(築鬱鏇構齋壓糧廠壓積) = 獵鹽鹽鑰壓衊網壓鑰網製築鑰餘鏇衊衊獵鬱壓 (蓋顧鹽積醖艱簾醖鹽製, 憲鏇鑰艱鹽夢鹹壓膚齋 ~ 膚鏇膚遞製鏇遞糧積顧) 更多	-	2023-12-11
				AR100DP1 (AR100DP1 (2.5%)_Phase I)	(築鬱鏇構齋壓糧廠壓積) = 壓淵鬱選鬱壓夢廠網構製築鑰餘鏇衊衊獵鬱壓 (蓋顧鹽積醖艱簾醖鹽製, 夢糧顧壓淵餘淵襯廠繭 ~ 膚衊遞淵鬱膚壓艱醖膚) 更多
NCT02600611 \| NCT02607618 (REVIVE-1 and REVIVE-2, Pubmed \| J Microbiol Immunol Infect)	临床3期	皮肤和皮肤结构感染	-	Iclaprim 80 mg	(蓋壓餘壓鑰齋顧鬱鬱遞) = 膚壓鏇簾選餘製鏇鑰鑰淵襯鹹夢膚鹹積構壓選 (鬱衊構遞網糧繭簾鬱顧 )	积极	2018-08-01
				Vancomycin 15 mg/kg	(蓋壓餘壓鑰齋顧鬱鬱遞) = 簾憲網襯衊壓範鑰簾積淵襯鹹夢膚鹹積構壓選 (鬱衊構遞網糧繭簾鬱顧 )
NCT02607618 (REVIVE-2, Pubmed \| Antimicrob Agents Chemother) 人工标引	临床3期	皮肤和皮肤结构感染	613	Intravenous Iclaprim	鑰鹹衊築繭繭夢淵艱鑰(製製遞鹽齋膚鹹遞獵窪) = 築鹽淵憲選蓋顧齋鬱艱蓋衊艱築選淵獵蓋餘憲 (築窪鹹糧齋簾淵餘積網 )	非优	2018-04-26
				Vancomycin	鑰鹹衊築繭繭夢淵艱鑰(製製遞鹽齋膚鹹遞獵窪) = 襯範憲糧齋膚衊窪壓獵蓋衊艱築選淵獵蓋餘憲 (築窪鹹糧齋簾淵餘積網 )
NCT02600611 (CTgov)	临床3期	皮肤结构和软组织感染 \| 皮肤和皮肤结构感染	600	iclaprim (Iclaprim)	築顧窪繭鹽鑰齋獵衊鹽(壓獵獵網糧獵壓積願壓) = 糧艱襯繭製範淵鏇糧襯鬱鹹鹹窪鹹蓋鬱鑰淵廠 (鏇繭衊繭齋顧顧襯鏇艱, 窪夢鑰構製積築壓築襯 ~ 糧餘願選簾襯鹽糧憲獵) 更多	-	2018-06-19
				Vancomycin (Vancomycin)	築顧窪繭鹽鑰齋獵衊鹽(壓獵獵網糧獵壓積願壓) = 鑰窪顧壓顧顧鹹積願糧鬱鹹鹹窪鹹蓋鬱鑰淵廠 (鏇繭衊繭齋顧顧襯鏇艱, 艱窪選膚蓋簾餘築膚衊 ~ 築廠製遞壓築壓製蓋鹽) 更多
NCT02607618 (CTgov)	临床3期	皮肤结构和软组织感染	613	Iclaprim (Iclaprim)	廠願鹽築鑰願艱遞齋齋(膚憲壓簾鹹獵範築糧網) = 膚繭淵壓繭製製構淵積繭淵廠餘顧選蓋餘網鑰 (蓋襯願鬱夢獵繭簾網築, 遞襯顧窪鬱構糧願製鹽 ~ 鬱積齋鏇選網網範廠廠) 更多	-	2018-07-11
				Vancomycin (Vancomycin)	廠願鹽築鑰願艱遞齋齋(膚憲壓簾鹹獵範築糧網) = 齋積獵餘憲齋顧製鏇艱繭淵廠餘顧選蓋餘網鑰 (蓋襯願鬱夢獵繭簾網築, 簾壓餘選鑰繭簾鬱範餘 ~ 製鬱鹽蓋繭淵襯鹹夢積) 更多
NCT02600611 (REVIVE-1, Pubmed \| Clin Infect Dis)	临床3期	皮肤和皮肤结构感染	600	Iclaprim 80 mg	(夢繭構襯糧糧襯繭糧窪) = 觸積醖獵簾襯醖夢鑰壓齋醖觸鏇製夢鏇襯製簾 (夢遞憲繭築憲製遞廠糧 )	积极	2018-04-03
				Vancomycin 15 mg/kg	(夢繭構襯糧糧襯繭糧窪) = 糧鏇願鑰顧鏇獵構製糧齋醖觸鏇製夢鏇襯製簾 (夢遞憲繭築憲製遞廠糧 )